Actionable news
All posts from Actionable news
Actionable news in MDXG: MiMedx Group, Inc,

Pieris Pharmaceuticals: The Blockbuster In Antibody Mimetics


Pieris is a very promising, early-stage antibody mimetic biotech company.

We discuss reasons and timing for long-term holding of PIRS.

We discuss their current lead candidates, and how they aren't the major asset of Pieris.

We believe the company to be a potential buyout target.

We give a 1-year price target $2.50-$3.40, depending on company direction.

Welcome to Altum Research's prized possession: Pieris Pharmaceuticals (NASDAQ:PIRS).

Dear reader: We have 7 lengthy sections in which we hope to give you a solid and thorough...